Figure 2.
Figure 2. Outcome at 7 years for 553 patients randomized to receive imatinib as initial therapy in the IRIS study. At 7 years 60% of patients were still taking imatinib in accordance with the study protocol.
 Reprinted with permission from O’Brien SG et al. Blood. 2008;112:76a.10

Outcome at 7 years for 553 patients randomized to receive imatinib as initial therapy in the IRIS study. At 7 years 60% of patients were still taking imatinib in accordance with the study protocol.
 Reprinted with permission from O’Brien SG et al. Blood. 2008;112:76a.10 

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal